Vladimir Vexler - Jan 4, 2023 Form 4 Insider Report for Coherus BioSciences, Inc. (CHRS)

Role: Chief Scientific Officer
Signature: /s/ McDavid Stilwell, as Attorney-in-Fact for Vladimir Vexler
Stock symbol: CHRS
Transactions as of: Jan 4, 2023
Transactions value $: -$53,663
Form type: 4
Date filed: 1/6/2023, 05:15 PM
Previous filing: Apr 5, 2022
Next filing: Jan 12, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CHRS	Common Stock	Tax liability	-$53.7K	-5.44K	-5.23%	$9.87	98.5K	Jan 4, 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CHRS	Stock Option (Right to Buy)	Award	$0	+80K		$0.00	80K	Jan 4, 2023	Common Stock	80K	$9.87	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares automatically withheld to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3.
F2	Includes 1 share acquired on November 15, 2022, pursuant to Coherus BioSciences, Inc. Employee Stock Purchase Plan.
F3	The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 4, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.